BOULDER, Colo., June 27, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI™ capsules in combination with ...

ARRAY BIOPHARMA ($ARRY) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.13 per share, beating estimates of $0.09 by $0.04 ...

Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015. Ron Squarer, Chief Executive Officer of Array, noted, ...

Array BioPharma (Nasdaq: ARRY) today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study ...

Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...

Hi, good morning everybody and thank you for joining us for Day Three, our final day. Here at Annual BofA Merrill Healthcare Conference in Vegas. We are certainly excited to be able to host Array ...

After Array BioPharma (NASDAQ: ARRY) announced quarterly results and shared some clinical news with investors on Tuesday, shares of the cancer-focused clinical-stage biotech jumped and were up 18% as ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: Normally ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Array BioPharma ...

Q2 adj loss $0.44/shr vs est loss of $0.55/shr Q2 rev $9.6 mln vs est $6.7 mln Shares up 17 pct in after-hours trade Feb 1 (Reuters) - Array BioPharma Inc posted a narrower-than-expected quarterly ...

BOSTON (CBS.MW) -- Shares of Array BioPharma jumped 16 percent in after-hours trading on Monday after the small biotech firm said it'll collaborate with Genentech on research into potential new cancer ...